Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...
SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced positive topline results from the BL-B01D1-301 trial. The trial has met one of the dual primary endpoints ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback